Journal Of Neurosurgery Publication Demonstrates Advantages Of ClearPoint Prism Neuro Laser Therapy System
Portfolio Pulse from Benzinga Newsdesk
ClearPoint Neuro, Inc. (NASDAQ:CLPT) announced preclinical results published in the Journal of Neurosurgery showing the ClearPoint Prism Neuro Laser Therapy System's accuracy and efficacy in brain tissue temperature measurement and lesion morphology. Conducted with Swedish partner Clinical Laserthermia Systems AB and led by Dr. John Rolston, the study supports the system's safety and precision, contributing to FDA clearance. The Prism System, featuring non-cooled neurosurgical laser applicators, simplifies neurosurgical procedures and is in limited release in the US.
March 11, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ClearPoint Neuro's Prism System demonstrates significant preclinical efficacy and safety, contributing to its FDA clearance and simplifying neurosurgical procedures.
The positive preclinical results and FDA clearance of the Prism System highlight ClearPoint Neuro's potential to lead in neurosurgical solutions. The study's success, especially in accuracy and efficiency, positions CLPT for increased adoption in academic medical centers, potentially boosting its market presence and investor confidence.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100